|
|
 |
Central nervous system agent
|
 |
Antianxiety agent
|
 |
Management of anxiety disorders or short-term relief of symptoms of anxiety.
|
 |
Adults: Initially 7.5 mg twice daily. May increase dosage by 5 mg/day at 2- to 3-day intervals if necessary. Maintenance dose is 20 to 30 mg/day in divided doses. Maximum dose is 60 mg/day. Take before or after meals.
|
 |
Category B
|
 |
Dizziness, nausea, headache, nervousness, excitement, and light-headedness.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
 |
|
|